CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced that Chairman and Chief Executive Officer Vlad Vitoc, M.D. will present at two investor conferences during the month of April: the 14th Annual LD Micro Invitational taking place April 8-9, 2024, in New York City; and the Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference taking place April 17-18, 2024..

芝加哥——（商业新闻短讯）——MAIA生物技术公司（纽约证券交易所美国代码：MAIA）（“MAIA”，以下简称“公司”）是一家临床阶段的生物制药公司，开发针对癌症的靶向免疫疗法，今天宣布，董事长兼首席执行官弗拉德·维托克医学博士将出席4月份的两次投资者会议：2024年4月8日至9日在纽约市举行的第14届LD Micro邀请赛；以及2024年4月17日至18日举行的来宝资本市场新兴增长虚拟医疗股权会议。。

LD Micro:

LD微型：

Presentation:

演示文稿：

04:30PM ET on April 09, 2024*

2024年4月9日美国东部时间下午04:30*

Format:

格式：

In-person and virtual

面对面和虚拟

Location:

地点：

Sofitel New York, New York City

纽约索菲特酒店

Conference registration:

会议注册：

Visit the conference website

访问会议网站

Livestream registration:

Livestream注册：

Visit Sequire Events

访问Sequire活动

1x1 meetings:

1x1会议：

Upon request by registered investors

应注册投资者的要求

Noble Capital Markets:

贵族资本市场：

Presentation:

演示文稿：

11:00AM ET on April 17, 2024*

11： 美国东部时间2024年4月17日上午00点*

Format:

格式：

Virtual

虚拟

Conference registration:

会议注册：

Visit the conference website

访问会议网站

1x1 meetings:

1x1会议：

Upon request by registered investors

应注册投资者的要求

*Please note that the presentation date and time are subject to change. Participants should refer to the final program agendas for up-to-date information.

*请注意，演示日期和时间可能会更改。参与者应参考最终计划议程以获取最新信息。

MAIA’s lead candidate is THIO, a small molecule telomere-targeting anticancer agent that acts by producing direct telomeric DNA damage and inducing cancer-specific immune responses. THIO’s efficacy in non-small cell lung cancer (NSCLC) is being evaluated in THIO-101, a Phase 2 go-to-market clinical trial nearing completion, which is expected to be the first completed clinical study of a telomere-targeting agent in the field of cancer drug discovery and treatment.

MAIA的主要候选药物是THIO，一种靶向端粒的小分子抗癌剂，通过产生直接的端粒DNA损伤和诱导癌症特异性免疫反应起作用。THIO在非小细胞肺癌（NSCLC）中的疗效正在THIO-101中进行评估，THIO-101是一项即将完成的第二阶段上市临床试验，预计将是端粒靶向剂在癌症药物发现和治疗领域的首次完成临床研究。

MAIA plans to pursue the FDA’s accelerated approval program for THIO..

MAIA计划推行FDA对THIO的加速批准计划。。

Recent news from MAIA’s THIO-101 trial includes:

MAIA THIO-101试验的最新消息包括：

Early completion of enrollment; topline data expected in second half of 2024; (press release, February 22, 2024)

提前完成注册；预计2024年下半年的顶线数据；（新闻稿，2024年2月22日）

Strong response rate of 38% in third-line treatment efficacy data; (press release, March 6, 2024).

三线治疗疗效数据的强应答率为38%；（新闻稿，2024年3月6日）。

Multiple paths to potential commercial approval of THIO under consideration; MAIA anticipates a final FDA decision on THIO in 2026; (MAIA Shareholder Letter 2024).

考虑中的THIO潜在商业批准的多种途径；MAIA预计FDA将于2026年对THIO做出最终决定；（MAIA股东信函2024）。

About MAIA Biotechnology, Inc.

关于MAIA Biotechnology，Inc。

MAIA is a targeted therapy, immuno-oncology company focused on the development and commercialization of potential first-in-class drugs with novel mechanisms of action that are intended to meaningfully improve and extend the lives of people with cancer. Our lead program is THIO, a potential first-in-class cancer telomere targeting agent in clinical development for the treatment of NSCLC patients with telomerase-positive cancer cells.

MAIA是一家靶向治疗的免疫肿瘤学公司，专注于开发和商业化具有新型作用机制的潜在一流药物，旨在有意义地改善和延长癌症患者的生命。我们的主要项目是THIO，它是临床开发中潜在的一流癌症端粒靶向剂，用于治疗端粒酶阳性癌细胞的NSCLC患者。

For more information, please visit www.maiabiotech.com..

有关更多信息，请访问www.maiabiotech.com。。

Forward Looking Statements

前瞻性声明

MAIA cautions that all statements, other than statements of historical facts contained in this press release, are forward-looking statements. Forward-looking statements are subject to known and unknown risks, uncertainties, and other factors that may cause our or our industry’s actual results, levels or activity, performance or achievements to be materially different from those anticipated by such statements.

MAIA警告说，除本新闻稿中包含的历史事实声明外，所有声明均为前瞻性声明。前瞻性陈述受到已知和未知风险、不确定性和其他因素的影响，这些因素可能导致我们或我们行业的实际结果、水平或活动、绩效或成就与此类陈述所预期的存在重大差异。

The use of words such as “may,” “might,” “will,” “should,” “could,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “project,” “intend,” “future,” “potential,” or “continue,” and other similar expressions are intended to identify forward looking statements. However, the absence of these words does not mean that statements are not forward-looking.

使用“可能”、“可能”、“将”、“应该”、“可能”、“预期”、“计划”、“预期”、“相信”、“估计”、“项目”、“打算”、“未来”、“潜力”或“继续”等词语以及其他类似表达旨在识别前瞻性陈述。然而，没有这些词语并不意味着声明不具有前瞻性。

For example, all statements we make regarding (i) the initiation, timing, cost, progress and results of our preclinical and clinical studies and our research and development programs, (ii) our ability to advance product candidates into, and successfully complete, clinical studies, (iii) the timing or likelihood of regulatory filings and approvals, (iv) our ability to develop, manufacture and commercialize our product candidates and to improve the manufacturing process, (v) the rate and degree of market acceptance of our product candidates, (vi) the size and growth potential of the markets for our product candidates and our ability to serve those markets, and (vii) our expectations regarding our ability to obtain and maintain intellectual property protection for our product candidates, are forward looking.

例如，我们就（i）临床前和临床研究以及我们的研究和开发计划的启动、时间、成本、进展和结果，（ii）我们将候选产品推进并成功完成临床研究的能力，（iii）监管备案和批准的时间或可能性，（iv）我们开发、制造和商业化候选产品以及改进制造过程的能力，（v）候选产品的市场接受率和程度，（vi）候选产品市场的规模和增长潜力以及我们服务这些市场的能力，以及（vii）我们对候选产品获得和维持知识产权保护能力的期望，都是前瞻性的。

All forward-looking statements are based on current estimates, assumptions and expectations by our management that, although we believe to be reasonable, are inherently uncertain. Any forward-looking statement expr.

所有前瞻性陈述均基于管理层当前的估计、假设和期望，尽管我们认为这些估计、假设和期望是合理的，但本质上是不确定的。任何前瞻性声明。